Zuretinol acetate

Drug Profile

Zuretinol acetate

Alternative Names: QLT-091001; Synthetic retinaldehyde; Synthetic retinoid

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QLT; Retinagenix LLC
  • Developer Novelion Therapeutics
  • Class Eye proteins; Retinaldehydes; Retinoids; Small molecules
  • Mechanism of Action Acyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Leber congenital amaurosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Leber congenital amaurosis; Retinitis pigmentosa

Highest Development Phases

  • Phase III Leber congenital amaurosis; Retinitis pigmentosa
  • Phase II Nyctalopia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Canada (PO, Liquid)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Germany (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top